A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people lose weight.

Recruiting now. Registry record last updated May 8, 2026.

Who can join: Adults 18 to 65, have obesity, BMI 35+.
What you take: Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 4 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 1Sponsor Nicholas SkertichDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 42

What this study is for

Primary condition: Obesity and Obesity-related Medical Conditions.

Full scientific study title: Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss.

Who can join

Age18 to 65SexAnyBMI35 or higher

Adults 18 to 65, have obesity, BMI 35+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Adult 18 to 65 years of age
Body Mass Index \>35 with comorbidity of Type 2 Diabetes and/or Hypertension and/or Hyperlipidemia and/or Obstructive Sleep Apnea OR Body Mass Index \>40 with or without comorbidity
Undergoing primary sleeve gastrectomy

Key exclusion criteria

Prior metabolic and bariatric surgery
Prior use of GLP-1 agonist
Prior history of pancreatitis
Personal/family history of medullary thyroid cancer or MEN type 2
Secondary cause of obesity

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Illinois1 site

Rush University Medical Center
Chicago, Illinois
Sr. Clinical Research Coordinator312-942-5500matthew_johnson@rush.edu

Follow this trial

We email you if NCT06734273 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: March 10, 2025. Expected completion: September 2028. Last updated on ClinicalTrials.gov: May 8, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.